Issues
-
Cover Image
Cover Image
About the Cover
Tumor survival depends on a nurturing environment and a tumor's ability to “stay below the radar” of the immune surveillance network. In this month's issue, Pickup et al. have identified a key molecule produced by pancreatic ductal carcinomas, G-CSF (granulocyte colony-stimulating factor), which induced developing granulocytes to differentiate into myeloid suppressor cells and promoted a protumor microenvironment. Removing G-CSF while subjecting mice with aggressive pancreatic ductal tumors to treatment with gemcitabine (a DNA synthesis inhibitor) had therapeutic benefit. A subset of patients have mutations that abrogate TGFβ signaling (similar to the mouse models used), so targeting G-CSF in these patients could potentially enhance their responses to treatment. Read more starting on page 718. Micrograph from Fig. 4C. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
Highlights from the Literature
Research Articles
Using Antigen-Specific B Cells to Combine Antibody and T Cell–Based Cancer Immunotherapy
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.